Novavax’s Upside Edge Amid Triple Risk Flags and a Bull‑HighVol Surge

Why the vaccine maker’s asymmetric payoff may outpace its historic drawdowns

NVAX Novavax, Inc.

In this report

01

Returns Overview

Period returns, alpha, cumulative performance, distributions

P. 2-3

→

02

Volatility Analysis

Annualized volatility, downside deviation, drawdowns

P. 4-5

→

03

Beta & Correlation

Trailing, upside, downside beta, systematic risk

P. 6-7

→

04

Risk-Adjusted Returns

Sharpe, Sortino, Calmar, Information, Treynor

P. 8-9

→

05

Market Regime Analysis

Bull/bear behavior, capture ratios

P. 10-11

→

06

Investment Highlights & Risk Summary

Executive summary, risk flags, rankings

P. 12-13

→

Returns Overview

Novavax, Inc. (NVAX) — Return Performance

Novavax, Inc. (NVAX) displayed a highly volatile return profile over the past five years, with pronounced swings between periods of strong outperformance and deep underperformance relative to its healthcare sector benchmark (XLV). The stock posted a 41.22% six‑month gain, delivering an alpha of 33.36% versus the sector, yet it suffered a -95.53% total return over five years, lagging the sector by -126.15%, highlighting substantial long‑term downside risk despite occasional short‑term rallies.

Period Returns vs S&P 500 & XLV

Monthly Returns Heatmap

NVAX

In the most recent month NVAX fell -13.49%, underperforming the sector by 2.36 percentage points, but over the three‑month horizon it rebounded with a 16.58% gain, generating +3.49% alpha versus XLV. The six‑month and one‑year periods show strong upside, with returns of 41.22% (+33.36% alpha) and 50.63% (+31.64% alpha), respectively, indicating the stock can capture significant sector outperformance in bullish regimes, while the two‑year and five‑year horizons reveal severe reversals, posting -25.04% (-60.26% alpha) and -95.53% (-167.34% alpha), underscoring a pronounced divergence between short‑term upside potential and long‑term downside risk.

Returns Overview

Novavax, Inc. (NVAX) — Return Charts

Volatility Analysis

Novavax, Inc. (NVAX) — Volatility Profile

Novavax exhibits exceptionally high price variability relative to the broader market, with an annualized volatility of 110.81% compared to the S&P 500's 17.78%, indicating more than six times the typical equity risk. The downside profile is severe: a downside deviation of 72.87% and a historic maximum drawdown of -98.82% over a three‑year window underscore the potential for near‑total capital loss, with the decline spanning from early February 2021 to February 2024 without any meaningful recovery. While short‑term volatility (70.27% over 60 days) remains slightly above its longer‑term 252‑day level of 68.45%, both measures are far beyond what most investors deem acceptable, positioning Novavax as a high‑risk, speculative exposure.

Volatility Metrics

NVAX

Novavax's volatility is more than sixfold the S&P 500 benchmark, reflecting extreme price swings that can erode portfolio value quickly. The downside deviation of 72.87% signals that losses on down‑market days are substantially larger than typical equity losses, and the -98.82% max drawdown illustrates a near‑total loss of invested capital over three years with no recovery to prior peaks. Although the recent 60‑day volatility (70.27%) is marginally higher than its 252‑day average (68.45%), both figures remain far above the market norm, confirming that short‑term risk remains elevated relative to its already high long‑term baseline.

Annualized volatility of Novavax is 110.81%, over six times the S&P 500's 17.78%.
Downside deviation stands at 72.87%, indicating large losses on negative days.
Maximum historical drawdown reached -98.82% with a three‑year duration and no recovery.
Current 60‑day volatility (70.27%) is slightly above the 252‑day average (68.45%).
Both short‑term and long‑term volatilities are far beyond typical equity risk thresholds.

Positive Characteristics
The slight decline in recent volatility relative to its historical peak suggests a modest stabilization.
Despite extreme risk metrics, the high volatility could attract traders seeking large price moves for speculative strategies.

Volatility Analysis

Novavax, Inc. (NVAX) — Volatility & Drawdown Charts

Beta & Correlation

Novavax, Inc. (NVAX) — Beta Profile

Novavax exhibits a trailing beta of 1.385 versus the S&P 500, placing it firmly in the aggressive category (>1.2). This indicates that the stock tends to amplify broad market movements, delivering roughly 38.5% more return (or loss) than the market on average. The upside beta of 1.394 exceeds the downside beta of 1.044, suggesting that price gains are more sensitive to positive market shocks than price declines are to negative shocks—a useful asymmetry for risk‑adjusted portfolio construction. The low R-squared of 0.049 and correlation of 0.222 with the S&P 500 imply that only about 5% of Novavax’s return variance is explained by overall market movements, leaving 95% as idiosyncratic. When measured against its healthcare sector benchmark (XLV), the sector beta of 1.393 mirrors the market beta, but the sector R-squared drops to 0.044, confirming that sector dynamics account for an even smaller slice of return variance. Consequently, most of Novavax’s risk is company‑specific rather than driven by broad market or sector trends.

Beta & Correlation Metrics

NVAX

Novavax’s market beta of 1.385 signals aggressive exposure to equity market swings, while its sector beta of 1.393 shows comparable sensitivity to healthcare‑sector movements. The asymmetric upside/downside betas (1.394 vs 1.044) mean that the stock tends to participate more fully in bullish phases than it does in bearish ones, offering a modest cushion during downturns but also amplifying gains when sentiment improves. With an R-squared of just 4.9% versus the S&P 500 and 4.4% versus XLV, diversification benefits are substantial; most volatility stems from firm‑specific drivers such as product pipelines, regulatory outcomes, and contract negotiations.

Trailing market beta (1.385) classifies Novavax as aggressive relative to the S&P 500.
Upside beta (1.394) exceeds downside beta (1.044), indicating greater participation in positive market moves.
R-squared of 4.9% with the market and 4.4% with the healthcare sector highlight dominant idiosyncratic risk.
Systematic risk accounts for only 4.9% of total variance, leaving 95.1% as company‑specific.
Sector beta (1.393) mirrors market beta, confirming that sector exposure does not add additional systematic risk beyond overall market sensitivity.

Positive Characteristics
High upside beta provides potential for outsized gains in bullish environments.
Low R-squared offers strong diversification benefits within a broader equity portfolio.
Comparable sector and market betas simplify risk attribution, focusing attention on firm‑specific catalysts.

Beta & Correlation

Novavax, Inc. (NVAX) — Rolling Beta

Positive Notes

High upside beta provides potential for outsized gains in bullish environments.

Low R-squared offers strong diversification benefits within a broader equity portfolio.

Comparable sector and market betas simplify risk attribution, focusing attention on firm‑specific catalysts.

Risk-Adjusted Returns

Novavax, Inc. (NVAX) — Risk-Adjusted Performance

Novavax, Inc. (NVAX) delivers modest risk‑adjusted returns over the measurement period. A Sharpe ratio of 0.352 indicates that total return exceeds the risk‑free rate by only about 35% of its total volatility, falling well short of the >1.0 threshold typically viewed as satisfactory. However, the Sortino ratio of 0.535 surpasses the Sharpe figure, suggesting that downside volatility is lower than overall volatility and that the stock’s return profile is relatively less penalized by negative deviations.

Risk-free rate: 3.63% (Fed Funds Rate)

Risk-Adjusted Metrics

NVAX

The Calmar ratio of 0.431 reflects a modest return relative to the worst historical drawdown, implying that periods of sharp decline have eroded a substantial portion of gains. An Information Ratio of 0.276 signals that active management has generated positive alpha, but not at a level (>0.5) considered consistently strong. The Treynor ratio of 28.161 is unusually high because it is expressed in percentage points per unit of systematic risk; this suggests that the stock’s excess return per beta is sizable, yet the elevated figure must be interpreted alongside the low Sharpe and Calmar metrics, which highlight heightened total and drawdown risk.

Sharpe ratio below 1.0 indicates overall underperformance on a risk‑adjusted basis.
Sortino ratio exceeds Sharpe, pointing to a relatively favorable downside volatility profile.
Calmar ratio under 0.5 reveals that worst drawdowns have significantly offset returns.
Information Ratio of 0.276 shows modest but positive alpha generation.
Treynor ratio is high, reflecting strong excess return per unit of systematic risk despite broader risk concerns.

Positive Characteristics
Sortino ratio above Sharpe suggests limited downside volatility.
Positive Information Ratio indicates the stock has delivered some consistent alpha.

Risk-Adjusted Returns

Novavax, Inc. (NVAX) — Rolling Sharpe & Sortino

Positive Notes

Sortino ratio above Sharpe suggests limited downside volatility.

Positive Information Ratio indicates the stock has delivered some consistent alpha.

Market Regime Analysis

Novavax, Inc. (NVAX) — Regime Behavior

Novavax exhibits pronounced sensitivity to market conditions, delivering strong outperformance in bullish environments but suffering amplified losses during downturns. In Bull-LowVol periods the stock generates an average monthly return of 9.03%, reflecting its ability to ride calm uptrends; however, even in a more turbulent Bull-HighVol regime returns drop to 5.76% while still remaining positive. The downside is stark: Bear-LowVol months see an average decline of -5.84%, and the stock’s performance deteriorates further to -10.19% in Bear-HighVol periods, indicating heightened vulnerability when markets are both falling and volatile. The upside capture of 236.3% versus a downside capture of 171.8% yields a capture ratio of 1.38, meaning Novavax captures roughly 38% more upside than downside relative to the S&P 500, but the elevated downside capture tempers the attractiveness of that asymmetry.

Current Market Regime: Bull-HighVol

Bull-LowVol = calm uptrend • Bull-HighVol = volatile uptrend • Bear-LowVol = orderly decline • Bear-HighVol = crisis

Regime Returns & Capture Ratios

NVAX

Novavax thrives in bullish regimes, especially when volatility is low, delivering double‑digit monthly gains that exceed the broader market. In Bull-HighVol conditions it still posts positive returns (5.76% avg), though the drag from heightened volatility curtails performance relative to calmer markets. Conversely, the stock is not defensive; during Bear-LowVol periods it loses -5.84% per month and in Bear-HighVol environments the loss deepens to -10.19%, reflecting a strong correlation with market declines and an amplified reaction when fear spikes. The capture ratio of 1.38 signals that while upside potential outpaces downside risk, the absolute magnitude of downside capture remains high, suggesting limited protection during market stress.

Market Regime Analysis

Novavax, Inc. (NVAX) — Regime & Capture Charts

Regime Timeline

Novavax’s average return in Bull-LowVol regimes (9.03%) is substantially higher than its performance in Bear-HighVol periods (-10.19%).
The stock’s upside capture of 236.3% indicates it outperforms the S&P 500 markedly during market rallies.
Downside capture of 171.8% shows that losses exceed the market’s declines, limiting its defensive appeal.
A capture ratio of 1.38 reflects a net positive asymmetry but is driven more by strong upside than limited downside.
Current Bull-HighVol regime suggests Novavax will likely generate modest positive returns (around 5‑6% monthly) while remaining exposed to volatility‑driven drawdowns.

Positive Characteristics
Exceptional upside capture in bullish markets provides significant participation in market rallies.
Even in volatile uptrends, the stock remains positive, delivering an average of 5.76% per month.
The capture ratio above 1.0 confirms that overall the stock captures more upside than downside relative to the benchmark.

Investment Highlights & Risk Summary

Novavax, Inc. (NVAX) — Summary & Implications

Novavax delivered a remarkable 1‑year total return of 50.6%, generating an alpha of 31.6% versus the S&P 500 and outpacing its healthcare sector benchmark by 36.1%. The upside capture ratio of 236.3% indicates that the stock participated strongly in market rallies, while a Sharpe ratio of 0.352 reflects modest excess return per unit of risk given its extreme volatility. However, the company’s risk profile is severe: annualized volatility stands at 110.8%, beta is 1.385, and the maximum drawdown over the period approached a total loss of 98.8%, underscoring an acute potential for capital erosion. Investors must weigh the high return upside against the pronounced downside asymmetry, as the downside capture ratio of 171.8% suggests amplified losses during market declines.

Summary Dashboard

Investment Highlights

1‑year return of 50.6% produced an alpha of +31.6% versus the S&P 500, demonstrating strong absolute outperformance.
Sector alpha of +36.1% shows Novavax beat its healthcare peers (XLV) by a wide margin.
Upside capture of 236.3% indicates the stock captured more than double the upside when the broader market rose.
Beta of 1.385 suggests the stock is more responsive than the market, providing leverage to bullish moves.

Risk-Return Rankings

NVAX HIGH

High‑return, high‑volatility profile with strong upside capture but extreme downside risk.

Strength: Exceptional 1‑year alpha (+31.6%) and sector outperformance (+36.1%).

Concern: Maximum drawdown of -98.8% and volatility of 110.8% signal severe capital loss potential.

Key Takeaways

Novavax’s return metrics are compelling, but they come with the highest risk flags among healthcare stocks.
The stock’s upside capture far exceeds its downside capture, creating an asymmetric payoff that favors bullish environments.
Volatility and beta levels indicate the security will move sharply in both directions, magnifying market swings.
Investors should be prepared for potential near‑total loss scenarios given the historic drawdown.

PORTFOLIO IMPLICATIONS

Novavax may serve as a high‑convexity satellite position within a diversified portfolio, offering outsized upside during strong market rallies while requiring tight risk controls such as low overall allocation or hedging. Its elevated beta and volatility mean it should be paired with lower‑beta, defensive holdings to temper portfolio variance and mitigate the impact of severe drawdowns.

NVAX

Related Reports

Visit finexus.net/reports for more reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.